|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase Ⅱ study显示文摘 | Steinbild S Arends J Medinger M | 2007 | Onkologie2007，30，12： | 1 |
| 2 | Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplanta- tion for plasma cell mye|oma 显示文摘 | Rueff J Medinger M Helm D | 2014 | Bio Blood Marrow Transplant2014，20，6： | 1 |
| 3 | Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status 显示文摘 | Medinger M Skoda R Gratwohl A | 2009 | Br J Haematol2009，146，2： | 1 |
| 4 | Phase I clinical study of AZD2171, an oral vascular endothelial growth factor sig- naling inhibitor, in patients with advanced solid tumors显示文摘 | Drevs J Siegert P Medinger M | 2007 | J Clin Oncol2007，25，21： | 1 |
| 5 | Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase Ⅱ study 显示文摘 | Steinbild S Arends J Medinger M | 2007 | Onkologie2007，30，12： | 1 |
| 6 | Phase Ⅰ clinical study of AZD2171 ,an oral vascular endothelial growth factor signaling inhibitor,in patients with advanced solid tumors 显示文摘 | DREVS J SIEGERT P MEDINGER M | 2007 | J Clin Oncol2007，25，21： | 1 |
| 7 | Personal diary:A patient's experience at an academic radiology department显示文摘 | Medinger C M | 2000 | Acad Radiol2000，7，6： | 1 |
| 8 | Phase Ⅰ clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor,in patients with liver metasta- ses from solid tumors显示文摘 | Mross K Drevs J Muller M Medinger M Marine D Hennig J | 2005 | Eur J Cancer2005，41，9： | 1 |
| 9 | Angiogenesis and vascular endothelial growth factor-/receptor expres- sion in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status 显示文摘 | Medinger M Skoda R Gratwohl A | 2009 | Br J Haematol2009，146，2： | 1 |
| 10 | Phase I clinical study AZD2171, an oral vascular endothelial growth facter signaling inhibitor,in patients with advanced solid tumors显示文摘 | DREVS J SIEGERT P MEDINGER M | 2007 | J Clin Oncol2007，25，21： | 1 |
| 11 | Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies 显示文摘 | MEDINGER M FISCHER N TZANKOV A | 2010 | J Oncol2010，10，15： | 1 |
| 12 | Angiogenesis and vas- cular endothelial growth factor 2/receptor expression in myeloproli ferative neoplasms:correlation with clinical pa- rameters and JAK2-V617F mutational status显示文摘 | Medinger M Skoda R Gratwchl A | 2009 | Br J Haematol2009，146，2： | 1 |
| 13 | Receptor tyrosine kinases: the main targets for new anticancer therapy显示文摘 | Drevs J Medinger M Schmidt-Gersbach C | 2003 | Curr Drug Targets2003，4，2： | 1 |
| 14 | Phase I clinical study of AZD2171,an oral vascular endothelial growth factor signaling inhibitor,in patients with advanced solid tumors显示文摘 | Drevs J Siegert P Medinger M | 2007 | J Clin Oncol2007，25，21： | 1 |
| 15 | Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms:correlation with clinical parameters and JAK2-V617F mutational status显示文摘 | MEDINGER M SKODA R GRATWCHL A | 2009 | Br J Haematol2009，146，2： | 1 |
| 16 | Angiogenesis and vascu- lar endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2- V617F mutational status显示文摘 | Medinger M Skoda R Gratwohl A | 2009 | Br J Haematol2009，146，： | 1 |
| 17 | Aplastic anemia:possible associations with lymphoproliferative neoplasms显示文摘 | Tzankov A Medinger M | 2014 | Int J Lab Hematol2014，36，： | 1 |
| 18 | Metronomic antiangiogenie therapy with capeeitahine and celecoxib in advanced tumor patients--results of a phase Ⅱ study 显示文摘 | Steinbild S Arends J Medinger M | 2007 | Onkologie2007，30，12： | 1 |
| 19 | Metmnomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients results of a phase II study显示文摘 | Steinbild S Arends J Medinger M | 2007 | Onkologie2007，30，12： | 1 |
| 20 | A phase I A, open - label, dose - escalating study of PTK787/ZK222584 administered orally on a continuous dosing schedule in patients with advanced cancer显示文摘 | DREVS J MEDINGER M MROSS K | 2010 | Anticancer Res2010，30，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员